FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 275 filers reported holding FATE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.99 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $89,000 | -10.1% | 3,975 | 0.0% | 0.01% | -75.0% |
| Q2 2022 | $99,000 | -35.7% | 3,975 | 0.0% | 0.02% | -17.2% |
| Q1 2022 | $154,000 | -33.9% | 3,975 | 0.0% | 0.03% | -27.5% |
| Q4 2021 | $233,000 | -7.2% | 3,975 | -6.0% | 0.04% | -11.1% |
| Q3 2021 | $251,000 | -31.6% | 4,230 | 0.0% | 0.04% | -22.4% |
| Q2 2021 | $367,000 | +5.2% | 4,230 | 0.0% | 0.06% | -3.3% |
| Q1 2021 | $349,000 | -9.4% | 4,230 | 0.0% | 0.06% | -9.1% |
| Q4 2020 | $385,000 | +127.8% | 4,230 | 0.0% | 0.07% | +106.2% |
| Q3 2020 | $169,000 | +76.0% | 4,230 | +51.4% | 0.03% | +88.2% |
| Q2 2020 | $96,000 | – | 2,794 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $197,709,000 | 22.51% |
| Redmile Group, LLC | 12,957,222 | $758,127,000 | 17.24% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $60,690,000 | 6.28% |
| Casdin Capital, LLC | 3,400,000 | $198,934,000 | 5.61% |
| Ally Bridge Group (NY) LLC | 270,000 | $15,798,000 | 5.52% |
| DAFNA Capital Management LLC | 372,160 | $21,775,000 | 5.48% |
| Tri Locum Partners LP | 142,032 | $8,310,000 | 3.27% |
| Kynam Capital Management, LP | 95,561 | $5,591,000 | 2.99% |
| Artal Group S.A. | 1,800,000 | $105,318,000 | 2.86% |
| Bellevue Group AG | 3,775,736 | $220,918,000 | 2.28% |